



This is a peer-reviewed, final published version of the following document, This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0>). and is licensed under Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0 license:

**Ye, Lin, Sanders, Andrew ORCID logoORCID:
<https://orcid.org/0000-0002-7997-5286> and Jiang, Wen G
(2023) Transglutaminase-4 (Prostate Transglutaminase), a
Potential Biological Factor and Clinical Indicator for the
Diagnosis and Prognosis of Prostate Cancer. *Anticancer
Research*, 43 (1). pp. 291-296. doi:10.21873/anticanres.16162**

Official URL: <http://doi.org/10.21873/anticanres.16162>

DOI: 10.21873/anticanres.16162

EPrint URI: <https://eprints.glos.ac.uk/id/eprint/12235>

Disclaimer

The University of Gloucestershire has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material.

The University of Gloucestershire makes no representation or warranties of commercial utility, title, or fitness for a particular purpose or any other warranty, express or implied in respect of any material deposited.

The University of Gloucestershire makes no representation that the use of the materials will not infringe any patent, copyright, trademark or other property or proprietary rights.

The University of Gloucestershire accepts no liability for any infringement of intellectual property rights in any material deposited but will remove such material from public view pending investigation in the event of an allegation of any such infringement.

PLEASE SCROLL DOWN FOR TEXT.

Review

Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer

LIN YE¹, ANDREW J. SANDERS^{1,2} and WEN G. JIANG¹

¹Cardiff University School of Medicine, CCMRC, Henry Wellcome Building, Cardiff, U.K.;

²School of Natural and Social Science, University of Gloucestershire, Francis Close Hall, Cheltenham, U.K.

Abstract. *Transglutaminase-4, also known as prostate transglutaminase, is a protein encoded by the TGM4 gene. TGase-4 was thought to be exclusively expressed in the prostate gland and has been suggested to be involved in certain medical conditions, such as infertility and possibly prostate cancer. In recent years, substantial progress has been made in the understanding of this unique protein in prostate cancer, with emerging clinical evidence. The present concise review summarised the current understanding of this intriguing enzyme in prostate cancer and presents an argument that TGase-4 is a useful indicator of both the development and progression of the disease.*

Human prostate transglutaminase, also known as transglutaminase-4 (TGM4), transglutaminase-P (TGP), protein-glutamine gamma-glutamyltransferase 4, and fibrinolyticase, is a protein encoded by the *TGM4* gene, located in chromosome 3 (chr3:44,874,608-44,914,990) (1, 2). The *TGM4* gene transcript codes a protein of 684 amino acids and was shown to be primarily located in prostate tissues and is responsive to androgen (3). Although early work had been focused on male infertility, the unique tissue distribution pattern and its portraited biological functions have led to more extensive research into its role in prostate cancer.

Correspondence to: Lin Ye, Cardiff University School of Medicine, CCMRC, Henry Wellcome Building, Academic Avenue, Heath Park, Cardiff, Wales CF14 4XN, U.K. Tel: +44 2920687861, e-mail: YeL@cardiff.ac.uk

Key Words: Transglutaminase-4, prostate transglutaminase, TGM4, prostate cancer, metastasis, review.



This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY-NC-ND) 4.0 international license (<https://creativecommons.org/licenses/by-nc-nd/4.0>).

Expression Profile of TGase-4 in Human Tissues

Although TGase-4 was demonstrated in early days to be almost exclusively expressed in the prostate gland, recent available resources using a wider human tissue profile and new technologies have largely shown that this conclusion does indeed stand. Figure 1A shows the levels of TGase-4 RNA (*TGM4* gene transcript) across a rather large number of human normal tissues which was obtained from the GTEx Portal (accessed on 11th October 2022). It is clear from this comprehensive dataset that the *TGM4* transcript is present at very high levels in the prostate gland, followed by the testis, although by a large margin. It is interesting that both tissues/organs are of the male reproductive system. A much lower expression has been observed in the skin, fallopian tubes, adrenal gland, intestine, urinary bladder, vagina, and lungs, with no difference between males and females, except in the fallopian tubes and vagina.

In human cell lines, the expression varies widely across different cell types from different tissues/organs (Figure 1B). It is interesting to note that cells derived from the bone marrow, proximal digestive system, brain, and female reproductive system tend to have high levels (Figure 1B). In normal prostate tissues, single cell sequencing has shown that *TGM4* transcript is largely observed in prostate glandular cells (Figure 1C).

The Biological Impact of TGase-4 in Prostate Cancer Cells

Like clinical studies, biological-oriented studies on TGase-4 are not extensive. In collaboration with Dr. Richard Ablin of the University of Arizona, we have carried out a number of investigations by creating cell line models from prostate cancer. In this respect, we have generated both over-expression and knockdown models in prostate cancer cells that

normally displayed either low or high expression levels of TGase-4. We have demonstrated in a series of *in vitro* assays, that high levels of TGase-4 in prostate cancer cells rendered them with a high degree of matrix adhesiveness, and increased migration, and invasiveness (4). Increased TGase-4 in prostate cancer cells also increased their degree of adhesiveness to vascular endothelial cells (5, 6). It was also demonstrated that exogenous TGase-4 was also able to induce epithelial-to-mesenchymal transition (EMT), a biological process fundamental to the progression of cancer (7).

Perhaps one of the most interesting findings is that *TGM4* is a highly responsive gene to male hormones (1). Recent findings from a murine-based prostate cancer model by Lopez-Bujanda *et al.* demonstrated that *TGM4* is a highly responsive gene to androgen in that it may vary (increase) by a fold of one thousand times along with *MSMb* and *Sink1* (8). *TGM4* is also one of the most up-regulated genes in prostate tumours in comparison with normal prostate tissues in the murine model.

TGase-4 in Clinical Prostate Cancer

The clinical association between TGase-4 and prostate cancer has been slowly emerging and is somewhat controversial. In early studies, TGase-4 transcript, by way of Northern blot and PCR, was found to be at low levels in prostate cancer compared with normal tissues (9). This pattern appears to be similar to another member of the transglutaminase family, namely tissue transglutaminase (TGase-2), which showed lower levels in prostate cancer tissues and prostate cancer cells than normal tissue and normal prostate epithelial cells (10). This was also supported by a transcript analysis from laser-dissected prostate tissues in that prostate cancer cells had lower levels of the *TGM4* transcript than normal prostate tissues (11). However, more recent studies appear to be in contrast. For example, an immunohistochemistry-based investigation has shown higher levels of TGase-4 protein in human prostate tumours than in associated normal tissues and that this high level is an indicator of a poor biochemical recurrence-free survival (12). We have also shown that in a selective prostate cancer cohort, there were increased levels of TGase-4 transcript in prostate tumours with a Gleason Score higher than 7 (13). From microarray data sets, it was clear that TGase-4, along with a few other gene products, are connected to tumorigenesis in the prostate (14). This has received support from a much larger study from the TCGA dataset as recently reported by Lopez-Bujanda *et al.* (8). The study, again using biochemical recurrence as a clinical indicator, found that high levels of *TGM4* gene transcript is linked to a significantly shorter survival. Amongst the tumour types compared, the degree of *TGM4* transcript rise was also the greatest in prostate cancer compared to other types, followed by leukaemia, squamous cell carcinoma of head and neck, and lung origins.

Using some recent technologies, namely MudPIT on a LTQ-Orbitrap XL mass spectrometer, Kim *et al.* discovered that TGase-4, along with TIMP1, SEFn PARK7, PSA, prostate acidic phosphatase (PAP), and MME, are significantly elevated in the prostatic secretions of patients with primary and recurrent prostate cancers (15). Perhaps the most direct evidence for the link between TGase-4 and prostate cancer within a larger cohort was reported in a recent study by Cao *et al.* (12). Using a clinical cohort of 159 patients with prostate cancer who received radical prostatectomy, the authors carried out immunohistochemical analyses of TGase-4 along with other markers and reported that TGase-4 was highly expressed in prostate tumour tissues compared with non-cancerous tissues. TGase-4 staining was also highly correlated with Gleason Scores and PSA levels, in line with early findings on TGase-4 transcript. One of the most interesting findings was the significant correlation between TGase-4 and the recurrence (biochemical) of prostate cancer, which, along with the Gleason score (but not PSA interestingly), was found to be an independent prognostic factor for the biochemical recurrence (12). However, the controversies remain from early days, including a recent study by Shan *et al.*, in which needle biopsies from 105 individuals with 'abnormal' PSA or abnormal findings on digital rectal examination indicated that 57 cases had prostate cancer (PCa) and 48 cases benign prostatic hyperplasia (BPH). A study that employed microarray technologies to identify differentially expressed genes, showed that *TGase-4* expression, along with that of *HOXA7* and *KRT15*, was significantly lower in prostate tissues compared with BPH tissues (16). This recent study is somewhat contradictory to other observations for the following reasons. First, the nature of the tissues. The study used biopsy tissues and did not carry out microdissection. It is likely that the biopsy samples contained a mixture of cell and tissue types including normal epithelial cells, stromal cells, and cells of other types and that different cell types and tissues express varying levels of TGase-4. Second, the study compared BPH and prostate cancer. It would have been ideal to perform additional comparisons and also include normal tissues. Indeed, *HOXA7* has been found to be highly expressed in liver cancer (17), ovarian cancer (18), squamous cell carcinoma of the oral cavity (19), and breast cancer (20), and be associated with disease progression in these tumour types. A similar trend for *KRT15* (keratin-15) to *HOXA7* was reported squamous cell lung carcinoma (21), and colorectal cancer (22). This would suggest that the cohort evaluated by Shan *et al.* should be reexamined or other methods to be used for validation. This possibility is partially validated by a study by Sequeiros *et al.*, in which TGase-4 expression was found to be lower in urinary extracellular vesicles from prostate cancer patients compared with that in patients with benign prostate conditions (23).

Thus, although there appears to be a close link between TGase-4 and prostate cancer, a clear conclusion is yet to be

drawn, largely due to the inconsistency amongst the clinically-oriented investigations. Whilst most studies indicate an over-expression of TGase-4 in prostate cancer when compared with normal and benign tissues, some of the studies have demonstrated otherwise. It was clear that some of the inconsistencies were due to the methodologies and the way that tissues were processed; others could be due to the specific comparisons performed, namely tumour *vs.* BPH *vs.* normal, tissues *vs.* cells, tissues *vs.* extracellular vesicles *etc.* It was also very interesting to observe that the inconsistencies bear similar hallmarks to the other important prostate marker, namely PSA, which the entire literature shows the controversies regarding its expression levels in normal, tumour, and BPH tissues. A recent example is that prostate cancer tissues, in particular those of high grade, had lower levels of PSA than low grade tumours and BPH tissues, which together with other reports indicate that PSA is a measure of the volume of the prostate gland and of prostate tumours rather than a specific tumour marker. TGase-4, with the limited number of available studies in the literature, may have similarities to PSA as a tissue marker. Thus, whilst studies using tissue and immunohistochemical methods appear to deliver more controversial findings, recent *TGM4* gene transcript-based studies appeared to be more consistent, which demonstrated TGM4 as a highly useful prognostic biomarker for patients with prostate cancer. This has shown reproducibly in some other mRNA-based studies, where the levels of the *TGM4* gene transcript were significantly higher in prostate cancer tissues than in benign prostate tissues (24, 25).

Would TGase-4 Be a Useful Prognostic Serum/Body Fluid Factor for Prostate Cancer and Prostatic Diseases?

Perhaps one of the most interesting and intriguing studies in assessing the validity of TGase-4 as a diagnostic or prognostic factor is a recent investigation by Drabovich *et al.* in which the level of TGase-4 in seminal plasma was determined in a series of patients (26). Significantly higher levels of TGase-4 were seen in patients with prostate cancer than in those with benign prostate conditions. The validation cohort of seminal plasma has returned with a marked increase in the ratio of TGase-4 between patients with prostate cancer (n=152) to those with benign biopsies (n=67) (Ratio 3.1, $p=0.00075$), making TGase-4 the only marker with a significant difference between the two groups out of nineteen candidate markers and six control markers including KLK3 (PSA) (Ratio 0.81, $p=0.11$). The study has also shown that seminal plasma and tissue biopsies, but not the serum, are mostly suited for ELISA and mass spectrometry-based selected reaction monitoring.

The comprehensive study by Drabovich *et al.* has also shown that TGase-4 concentration in seminal plasma is more

than two thousand times higher than that in blood serum (26). It is interesting to note that the study did not find TGase-4 in blood serum as a useful marker in distinguishing those with prostate cancer from those without, a sharp contrast to TGase-4 in seminal plasma. This convincing study thus suggests that seminal TGase-4 is a potential diagnostic marker for prostate cancer to be detected in seminal fluid or prostate tissue and instead TGase-4 in blood serum may not be a suitable sample type for the test. This may also provide some clue as to why there has been so few studies on TGase-4 in blood serum. The study has also shown that TGase-4 expression in younger males (age <40 years) tends to be significantly higher compared to that in those with higher age, >70 years of age ($p<0.01$). A similar and striking difference was found for blood serum TGase-4.

Sequeiros *et al.*, whilst investigating protein markers in the urinary extracellular vesicle, found that the levels of TGM4 in samples of prostate cancer were lower than those from benign conditions (23).

TGase-4 as a Therapeutic Target

With the evidence supporting an important role of Tgase-4 in prostate cancer, whether TGase-4 may be considered as a therapeutic target has raised interest and is a subject of recent investigations. A recent report by Lopez-Bujanda *et al.* showed that TGase-4 is a potential immunogenic target for prostate cancer and that immune cells treated with TGase-4 can elicit anti-tumour activities *in vitro* (8). The study also found that patients (30%) who were treated with granulocyte-macrophage colony-stimulating factor gene-transduced irradiated prostate cancer vaccine cells (GVAX) responded by producing anti-TGM4 IgG and this immunogenic response appears to be connected with a lower chance of PSA recurrence. These intriguing results will undoubtedly be followed by more intensive investigations.

Perspectives

TGase-4, a protein primarily expressed in the prostate gland, has an important biological impact on prostate cancer cells. Clinically, there is increasing evidence that its presence and levels in seminal plasma and in prostate cancer tissues present a diagnostic and prognostic opportunity in clinical prostate cancer. There remain significant challenges in elucidating the expression pattern of both the protein and gene transcript of TGase-4 in tissues. Whilst it was clear that seminal TGase-4 protein appears to be a good diagnostic factor for prostate cancer, the importance of the protein levels in blood serum and tissues remains elusive and certainly deserves further investigation. Although the biological impact of TGase-4 on prostate cancer has been investigated to some degree, given that the protein can be

readily detected in body fluids, the full profile of the protein in normal prostate epithelial cells and prostate cancer cells needs further in-depth study. Finally, there is exciting evidence to indicate that TGase-4 can be used as a target for immunotherapy. Whether it can also be used as a target for other approaches remains an interesting topic.

Conflicts of Interest

The Authors declare that there are no conflicts of interest in relation to this study.

Authors' Contributions

LY, AS and WGJ drafted and revised the manuscript.

References

- Gentile V, Grant FJ, Porta R and Baldini A: Localization of the human prostate transglutaminase (type IV) gene (TGM4) to chromosome 3p21.33-p22 by fluorescence in situ hybridization. *Genomics* 27(1): 219-220, 1995. PMID: 7665178. DOI: 10.1006/geno.1995.1032
- Grant FJ, Taylor DA, Sheppard PO, Mathewes SL, Lint W, Vanaja E, Bishop PD and O'Hara PJ: Molecular cloning and characterization of a novel transglutaminase cDNA from a human prostate cDNA library. *Biochem Biophys Res Commun* 203(2): 1117-1123, 1994. PMID: 7916568. DOI: 10.1006/bbrc.1994.2298
- Dubbink HJ, Verkaik NS, Faber PW, Trapman J, Schröder FH and Romijn JC: Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase. *Biochem J* 315 (Pt 3): 901-908, 1996. PMID: 8645175. DOI: 10.1042/bj3150901
- Davies G, Ablin RJ, Mason MD and Jiang WG: Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. *J Exp Ther Oncol* 6(3): 257-264, 2007. PMID: 17552366.
- Jiang WG, Ablin RJ, Kynaston HG and Mason MD: The prostate transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. *Microvasc Res* 77(2): 150-157, 2009. PMID: 18983858. DOI: 10.1016/j.mvr.2008.09.010
- Jiang WG, Ye L, Sanders AJ, Ruge F, Kynaston HG, Ablin RJ and Mason MD: Prostate transglutaminase (TGase-4, TGaseP) enhances the adhesion of prostate cancer cells to extracellular matrix, the potential role of TGase-core domain. *J Transl Med* 11: 269, 2013. PMID: 24161123. DOI: 10.1186/1479-5876-11-269
- Ablin RJ, Owen S and Jiang WG: Prostate transglutaminase (TGase-4) induces epithelial-to-mesenchymal transition in prostate cancer cells. *Anticancer Res* 37(2): 481-487, 2017. PMID: 28179293. DOI: 10.21873/anticancer.11340
- Lopez-Bujanda ZA, Obradovic A, Nirschl TR, Crowley L, Macedo R, Papachristodoulou A, O'Donnell T, Laserson U, Zarif JC, Reshef R, Yuan T, Soni MK, Antonarakis ES, Haffner MC, Larman HB, Shen MM, Muranski P and Drake CG: TGM4: an immunogenic prostate-restricted antigen. *J Immunother Cancer* 9(6): e001649, 2021. PMID: 34193566. DOI: 10.1136/jitc-2020-001649
- An G, Meka CS, Bright SP and Veltri RW: Human prostate-specific transglutaminase gene: promoter cloning, tissue-specific expression, and down-regulation in metastatic prostate cancer. *Urology* 54(6): 1105-1111, 1999. PMID: 10604718. DOI: 10.1016/s0090-4295(99)00298-8
- Birckbichler PJ, Bonner RB, Hurst RE, Bane BL, Pitha JV and Hemstreet GP 3rd: Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma. *Cancer* 89(2): 412-423, 2000. PMID: 10918174. DOI: 10.1002/1097-0142(20000715)89:2<412::aid-cnrcr29>3.0.co;2-o
- Adler D, Lindstrot A, Buettner R and Wernert N: Analysis of laser-microdissected prostate cancer tissues reveals potential tumor markers. *Int J Mol Med* 28(4): 605-611, 2011. PMID: 21743959. DOI: 10.3892/ijmm.2011.746
- Cao Z, Wang Y, Liu ZY, Zhang ZS, Ren SC, Yu YW, Qiao M, Zhai BB and Sun YH: Overexpression of transglutaminase 4 and prostate cancer progression: a potential predictor of less favourable outcomes. *Asian J Androl* 15(6): 742-746, 2013. PMID: 23974364. DOI: 10.1038/aja.2013.79
- Jiang WG, Ablin RJ, Kynaston HG and Mason MD: Expression of the prostate type transglutaminase (tgase-4) in clinical prostate cancer. 98th AACR Annual Meeting 67(9_Supplement): 2659, 2007.
- Fujita A, Gomes LR, Sato JR, Yamaguchi R, Thomaz CE, Sogayar MC and Miyano S: Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates. *BMC Syst Biol* 2: 106, 2008. PMID: 19055846. DOI: 10.1186/1752-0509-2-106
- Kim Y, Ignatchenko V, Yao CQ, Kalatskaya I, Nyalwidhe JO, Lance RS, Gramolini AO, Troyer DA, Stein LD, Boutros PC, Medin JA, Semmes OJ, Drake RR and Kislinger T: Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer. *Mol Cell Proteomics* 11(12): 1870-1884, 2012. PMID: 22986220. DOI: 10.1074/mcp.M112.017889
- Shan M, Xia Q, Yan D, Zhu Y, Zhang X, Zhang G, Guo J, Hou J, Chen W, Zhu T, Zhang X, Xu J, Wang J, Ding T and Zheng J: Molecular analyses of prostate tumors for diagnosis of malignancy on fine-needle aspiration biopsies. *Oncotarget* 8(62): 104761-104771, 2017. PMID: 29285211. DOI: 10.18632/oncotarget.22289
- Tang B, Qi G, Sun X, Tang F, Yuan S, Wang Z, Liang X, Li B, Yu S, Liu J, Huang Q, Wei Y, Zhai R, Lei B, Guo X and He S: HOXA7 plays a critical role in metastasis of liver cancer associated with activation of Snail. *Mol Cancer* 15(1): 57, 2016. PMID: 27600149. DOI: 10.1186/s12943-016-0540-4
- Ota T, Gilks CB, Longacre T, Leung PC and Auersperg N: HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. *Reprod Sci* 14(6): 605-614, 2007. PMID: 17959889. DOI: 10.1177/1933719107307781
- Duan X, Chen H, Ma H and Song Y: The expression and significance of the HOXA7 gene in oral squamous cell carcinoma. *J Oral Sci* 59(3): 329-335, 2017. PMID: 28529281. DOI: 10.2334/josnusd.16-0634
- Zhang Y, Cheng JC, Huang HF and Leung PC: Homeobox A7 stimulates breast cancer cell proliferation by up-regulating estrogen receptor-alpha. *Biochem Biophys Res Commun* 440(4): 652-657, 2013. PMID: 24099775. DOI: 10.1016/j.bbrc.2013.09.121
- Sanchez-Palencia A, Gomez-Morales M, Gomez-Capilla JA, Pedraza V, Boyero L, Rosell R and Fárez-Vidal ME: Gene expression profiling reveals novel biomarkers in nonsmall cell

- lung cancer. *Int J Cancer* 129(2): 355-364, 2011. PMID: 20878980. DOI: 10.1002/ijc.25704
- 22 Rao X, Wang J, Song HM, Deng B and Li JG: KRT15 overexpression predicts poor prognosis in colorectal cancer. *Neoplasma* 67(2): 410-414, 2020. PMID: 31884802. DOI: 10.4149/neo_2019_190531N475
- 23 Sequeiros T, Rigau M, Chiva C, Montes M, Garcia-Grau I, Garcia M, Diaz S, Celma A, Bijnsdorp I, Campos A, Di Mauro P, Borrós S, Reventós J, Doll A, Paciucci R, Pegtel M, de Torres I, Sabidó E, Morote J and Olivan M: Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer. *Oncotarget* 8(3): 4960-4976, 2017. PMID: 27903962. DOI: 10.18632/oncotarget.13634
- 24 Cancer Genome Atlas Research Network: The molecular taxonomy of primary prostate cancer. *Cell* 163(4): 1011-1025, 2015. PMID: 26544944. DOI: 10.1016/j.cell.2015.10.025
- 25 Bhowal A, Majumder S, Ghosh S, Basu S, Sen D, Roychowdhury S, Sengupta S and Chatterji U: Pathway-based expression profiling of benign prostatic hyperplasia and prostate cancer delineates an immunophilin molecule associated with cancer progression. *Sci Rep* 7(1): 9763, 2017. PMID: 28852180. DOI: 10.1038/s41598-017-10068-9
- 26 Drabovich AP, Saraon P, Drabovich M, Karakosta TD, Dimitromanolakis A, Hyndman ME, Jarvi K and Diamandis EP: Multi-omics biomarker pipeline reveals elevated levels of protein-glutamine gamma-glutamyltransferase 4 in seminal plasma of prostate cancer patients. *Mol Cell Proteomics* 18(9): 1807-1823, 2019. PMID: 31249104. DOI: 10.1074/mcp.RA119.001612
- 27 Pontén F, Jirstrom K and Uhlen M: The Human Protein Atlas—a tool for pathology. *J Pathol* 216(4): 387-393, 2008. PMID: 18853439. DOI: 10.1002/path.2440

Received October 19, 2022

Revised October 25, 2022

Accepted October 26, 2022